← Leaderboards
Stanley J Watowich
University Of Texas Medical Br Galveston
$2,525,942
Attributed
$4,521,225
Total exposure
8
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $999.4K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,521,225 · 8
By mechanism
U01$2,992,925 · 1
R21$1,478,328 · 3
P41$49,972 · 4
Top collaborators
- Peter J Davies3 shared
- Suzanne Marie Tomlinson3 shared
Most similar at University Of Texas Medical Br Galveston
Same institution · by research overlap
- Scott C Weaver$56,593,623
- Slobodan Paessler$18,721,420
- Shinji Makino$11,956,927
- David H Walker$27,320,724
- Robert O. Fox$2,552,476
Others in their field
Top investigators on “Research Personnel”
- David Heimbrook · Leidos Biomedical Research, Inc.$701,463,488
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Leonard Freedman · Leidos Biomedical Research, Inc.$557,978,666
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David R. Weir · University Of Michigan At Ann Arbor$364,053,504
- Judith S. Currier · University Of California Los Angeles$284,675,012
Research focus
Research PersonnelEnsureSuccessProgramsUnited States National Institutes Of HealthInhibitor/AntagonistSmall MoleculeGrowthBaseLeadIn VitroAreaTechnologyAntiviral AgentsDesignDrug DevelopmentPermeabilityBiotechnologyStructureResourcesInstitutionHealthcareFundingCells
Grant awards (15)
Gulf Coast Consortia (GCC) Research Evaluation and Commercialization Hub$998,317
U01 · FY2025 · GM
Gulf Coast Consortia (GCC) Research Evaluation and Commercialization Hub$995,246
U01 · FY2024 · GM
Gulf Coast Consortia (GCC) Research Evaluation and Commercialization Hub$999,362
U01 · FY2023 · GM
Development of NNMT inhibitors as novel interventions to activate quiescent muscle stem cells and improve age-related muscle degeneration$197,500
R21 · FY2020 · AG · contact PI
Development of NNMT inhibitors as novel interventions to activate quiescent muscle stem cells and improve age-related muscle degeneration$237,000
R21 · FY2019 · AG · contact PI
Elucidating the Mechanism of Novel Dengue Antivirals$185,164
R21 · FY2009 · AI · contact PI
Elucidating the Mechanism of Novel Dengue Antivirals$185,164
R21 · FY2008 · AI · contact PI
Elucidating the Mechanism of Novel Dengue Antivirals$226,500
R21 · FY2007 · AI · contact PI
VENEZUELAN EQUINE ENCEPHALOMYELITIS VIRUS$8,145
P41 · FY2007 · RR · contact PI
VENEZUELAN EQUINE ENCEPHALOMYELITIS VIRUS$7,529
P41 · FY2006 · RR · contact PI
VENEZUELAN EQUINE ENCEPHALOMYELITIS VIRUS$18,469
P41 · FY2005 · RR
VENEZUELAN EQUINE ENCEPHALOMYELITIS VIRUS$10,848
P41 · FY2004 · RR
STRUCTURE OF VEE VIRUS NSP2 PROTEASE: BIOLOGICAL WARFARE$4,981
P41 · FY2004 · RR
Novel Countermeasures to Hemorrhagic Fever Viruses$223,500
R21 · FY2003 · AI
Novel Countermeasures to Hemorrhagic Fever Viruses$223,500
R21 · FY2002 · AI